Strata Oncology, Inc., a revolutionary precision oncology company that is revolutionizing cancer treatment, has been honored with an honorable mention in the health category of Fast Company’s 2023 World Changing Ideas Awards for its Immunotherapy Response Score, a breakthrough multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit.
This highly prestigious award recognizes the most innovative products, daring social initiatives, and creative projects that are transforming the way we live and interact with the world. Strata is proud to be among the select few to be honored with this prestigious award.
For the second year in a row, Strata’s groundbreaking advances in precision oncology have been recognized with a World Changing Ideas Award. Last year, the company’s Precision Indications for Approved Therapies (Strata PATH) trial was awarded an honorable mention in the health category.
This trial was designed to assess the efficacy and safety of a variety of FDA-approved cancer therapies in newly identified patient populations based on biomarkers. Strata’s ongoing commitment to cancer research is helping to revolutionize cancer treatment, and the recognition of their efforts is a testament to this.
Strata Oncology’s precision oncology platform has reached a major milestone with the recent Medicare coverage of their novel Strata Select™ pan-solid tumor molecular profiling test. This test includes the Immunotherapy Response Score and is available for patients with advanced cancer who meet specified criteria, further demonstrating the platform’s potential to provide personalized cancer care that can improve patient outcomes.
Strata Oncology is honored to be recognized for the second consecutive year by Fast Company’s World Changing Ideas Awards. This recognition is further evidence of our dedication to advancing precision oncology and improving patient outcomes.
With Medicare coverage for Strata Select, we are closer to our mission of providing personalized and effective cancer treatment to all who can benefit from it. We will continue to innovate and collaborate to make precision oncology accessible to everyone.
Fast Company’s World Changing Ideas Awards have crowned 45 winners, 216 finalists, and more than 300 honorable mentions in 2023! With health, climate, energy, and AI among the most popular categories, the awards received an impressive pool of over 2,200 entries from around the globe, from Italy to Singapore to New Zealand.
A panel of Fast Company editors and reporters carefully selected the winners and finalists, highlighting inspiring and innovative ideas in urban design, education, nature, politics, technology, and corporate social responsibility.
It’s inspiring to witness the ingenuity and originality of this year’s honorees! Despite the challenging times we live in, the entrepreneurs, companies, and nonprofits featured in this package demonstrate the potential to solve some of society’s most pressing problems.
From housing to equity to sustainability, Fast Company’s journalists have highlighted some of the most inspiring and impactful work being done today. We’re eager to see how these projects evolve, as well as the ways in which they will serve to motivate others to create their own solutions.
About the World Changing Ideas Awards
Fast Company’s annual World Changing Ideas Awards is a celebration of the world’s most innovative and impactful social good projects. Recognizing products and concepts that make the world a better place, a panel of experts selects the winners, finalists, and honorable mentions based on their potential for positive change.
With the mission of applauding ingenuity and fueling progress, the awards bring much-deserved attention to ideas that have the capacity to create real, lasting impact. Let’s applaud the innovators working towards solving the world’s most pressing problems and join them in their mission.
About Strata Oncology
At Strata Oncology, Inc., our mission is to revolutionize the way cancer is treated. We do this by combining molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver the best possible treatment for each patient with cancer. Our goal is to make sure that every patient receives the optimal treatment for their specific cancer.